Regentis Biomaterials Targets Major Gap in Knee Cartilage Repair with Off-the-Shelf Implant
Regentis Biomaterials Ltd. is advancing GelrinC, a cell-free hydrogel implant for knee cartilage repair, which could address a significant unmet need in the U.S. market where no off-the-shelf regenerative solution currently exists.
Regentis Biomaterials Ltd. (NYSE American: RGNT) is positioning itself to address a major gap in the knee cartilage repair market with its off-the-shelf regenerative implant, GelrinC. The cell-free hydrogel implant is designed to repair knee cartilage damage through a single procedure lasting approximately 10 minutes, offering a potential alternative to existing treatments that often require multiple surgeries or lengthy preparation.
In the United States, roughly 472,500 arthroscopic knee procedures each year involve cartilage damage, yet there is no approved off-the-shelf regenerative solution capable of restoring hyaline-like cartilage. Current options include microfracture procedures, which may not provide durable cartilage repair, and complex cell-based therapies that require multiple surgeries and extensive preparation. GelrinC is designed as a ready-to-use implant that supports native cartilage regeneration over time, potentially simplifying the treatment process and improving patient outcomes.
The product has already received CE Mark approval in Europe and is advancing through a pivotal U.S. FDA trial that is now more than 50% enrolled. Regentis is also preparing for potential commercialization, highlighted by a newly patented solvent-free manufacturing process that increased production yield by 400%. Additionally, the company is building physician adoption infrastructure across Europe to support the implant's rollout.
Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, aims to regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC, the lead product, is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The company estimates that approximately 470,000 cases for cartilage knee repair occur annually in the U.S., where no off-the-shelf treatment is currently available.
For more information on the latest news and updates relating to RGNT, visit the company's newsroom at https://ibn.fm/RGNT. To view the full article on BioMedWire, visit https://ibn.fm/TrCv1.